title: Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
authors.forename: Shane A
authors.initials: SA
authors.lastname: Gangatharan
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Carney
authors.forename: Lynda J
authors.initials: LJ
authors.lastname: Campbell
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.forename: Melita K
authors.initials: MK
authors.lastname: Kenealy
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use*; D020732:Cytogenetic Analysis; D006801:Humans; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine